IDSA
Infectious Diseases Society of America

hivma
hiv medicine association

OXFORD

Sex Differences in Influenza: The Challenge Study Experience

Luca T. Giurgea,[1] Adriana Cervantes-Medina,[1] Kathie-Anne Walters,[2] Kelsey Scherler,[2] Alison Han,[1] Lindsay M. Czajkowski,[1] Holly Ann Baus,[1] Sally Hunsberger,[3] Sabra L. Klein,[4] John C. Kash,[5] Jeffery K. Taubenberger,[5] and Matthew J. Memoli[1]

[1]LID Clinical Studies Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA, [2]Institute for Systems Biology, Seattle, Washington, USA, [3]Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA, [4]W. Harry Feinstone Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA, and [5]Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Background. Preclinical animal studies and retrospective human studies suggest that adult females have worse outcomes from influenza than males. Prospective studies in humans are missing.

Methods. Data from 164 healthy volunteers who underwent influenza A/California/04/2009/H1N1 challenge were compiled to compare differences between sexes. Baseline characteristics, including hormone levels, hemagglutination inhibition (HAI) titers, neuraminidase inhibition (NAI) titers, and outcomes after challenge were compared. Linear and logistic regression models were built to determine significant predictor variables with respect to outcomes of interest.

Results. HAI titers were similar between the sexes, but NAI titers were higher in males than females at 4 weeks and 8 weeks postchallenge. Females were more likely to have symptoms (mean, 0.96 vs 0.80; $P = .003$) and to have a higher number of symptoms (median, 3 vs 4; $P = .011$) than males. Linear and logistic regression models showed that prechallenge NAI titers, but not HAI titers or sex hormone levels, were predictive of all shedding and symptom outcomes of interest.

Conclusions. Females in our cohorts were more likely to be symptomatic and to have a higher number of symptoms than males. NAI titers predicted all outcomes of interest and may explain differential outcomes between the sexes.

Keywords. influenza; sex differences; neuraminidase; hemagglutinin; estrogen; testosterone.

Among humans, males and females reportedly differ in the prevalence, pathogenesis, prognosis, and treatment responses for many viral infectious diseases, including coronavirus disease 2019, hepatitis C, human immunodeficiency virus (HIV), and influenza [1, 2]. Biological sex (ie, differences caused by sex chromosome complement and sex steroid hormone concentrations) can impact susceptibility to viruses by affecting antiviral immune responses that restrict virus replication as well as responses that promote inflammation and contribute to tissue damage and prolonged disease [3]. Male–female differences in exposure to and outcomes of viral infections, including influenza, can also be caused by differences in the behaviors, occupations, and even societal norms that define our genders [4]. The complex psychological and cultural interactions between biological sex and gender can complicate interpretation of

observational, epidemiological studies reporting male–female differences in infectious disease outcomes.

Preclinical animal models have been used to test hypotheses about the mechanisms mediating sex differences in influenza pathogenesis and responses to inactivated influenza vaccines. These studies collectively show that adult female mice develop greater inflammation and immunity following infection with either H1N1 or H3N2 viruses, which contribute to more severe outcomes in females compared with males [5–8]. Protection against severe outcomes from influenza A virus infections in males is mediated by androgens, which dampen inflammation, including recruitment of monocytes and eosinophils into the lungs of male mice [9]. In humans, epidemiological studies suggest that women of reproductive age have higher rates of influenza [10] and influenza-related hospitalizations [11] compared to men of the same age, though this trend is reversed prior to puberty and at older ages [12]. Pregnancy is a known female-specific risk factor for hospitalization among patients with influenza, but it does not solely explain all female-biased severe outcomes from influenza [13, 14].

In addition to sex-specific differences in infectious disease pathogenesis, a number of preclinical and clinical studies illustrate that females tend to have greater immune responses, reporting of adverse reactions, and even efficacy of vaccines that protect against a number of viral diseases, including influenza

[8, 15, 16]. For example, following vaccination with trivalent inactivated vaccine (TIV), women of reproductive age have worse injection site discomfort and greater hemagglutination inhibition (HAI) titers and neutralizing antibody titers than men [17], with these differences observed in response to either a full dose or a half dose of TIV [18]. Although HAI and neutralizing antibody titers have been considered a correlate of protection, there is a growing appreciation that neuraminidase inhibition (NAI) titers also serve as a correlate of protection because these antibodies reduce influenza viral burden through impairment of viral budding from infected cells [19–21]. Sex differences in NAI, however, have not been evaluated or reported.

Influenza challenge studies provide a unique opportunity for the careful study of a homogenous group of participants controlled for many of the confounders present in retrospective studies. Participants are typically all young, healthy volunteers, thereby controlling for confounding by comorbidities and age. Pregnancy is an exclusion factor for participation in challenge studies. All participants are subjected to equal doses of challenge virus, thereby eliminating exposure differences secondary to occupation and other gender-related factors, which may underlie some of the differences between sexes [22]. Finally, data collection and follow-up in challenge studies are standardized, attenuating differences in reporting and eliminating differences in access to care. We reviewed data from 4 different influenza challenge studies performed by our group, abbreviated as H1N1 pdMIST [23], HAI pdMIST [19], FLU-V [24], and CR6261 [25]. H1N1 pdMIST was the first challenge study using Good Manufacturing Practice–produced wild-type influenza, designed to determine in a dose-escalating manner the optimal dose of virus capable of causing mild to moderate disease in >60% of participants. HAI pdMIST recruited participants with high and low HAI titers to evaluate anti-hemagglutinin (HA) and anti-neuraminidase (NA) antibodies as correlates of protection. The FLU-V study evaluated the efficacy of a novel influenza vaccine against placebo in reducing shedding and symptoms after influenza challenge. Finally, the CR6261 study evaluated the efficacy of a monoclonal antibody infusion (compared to placebo) in reducing shedding and symptoms after influenza challenge. Using data from these 4 influenza challenge studies, we set out to characterize differences between males and females and explore the underlying factors contributing to these differences.

MATERIALS AND METHODS

Study Design

Data collected from 4 previous H1N1 influenza challenge studies was aggregated. Selection criteria for analysis included only participants who received a dose of challenge virus of 10^7 median tissue culture infectious dose$_{50}$ and excluded participants who received other experimental vaccine or therapeutic products as a part of the treatment arms in these studies (Table

Table 1. Datasets Included in Study With Study Descriptions and Selection Criteria Applied to Each Study

Study	Study Description	Original Study HAI Titer Criteria	Data Selection for Sex Differences Analysis
H1N1 pdMIST	Influenza dose escalation challenge study designed to determine the optimal dose for influenza challenge	≤1:40	Participants who received influenza challenge at 10^7 TCID$_{50}$
HAI pdMIST	Influenza challenge comparing participants with low and high HAI titers designed to investigate correlates of immunity	<1:40 and ≥ 1:40	All participants
FLU-V	Phase 2 placebo-controlled study assessing efficacy of a novel conserved capsid peptide vaccine through vaccination and subsequent influenza challenge	<1:40	Participants who received placebo
CR6261	Phase 2 placebo-controlled study assessing efficacy of a monoclonal antibody against HA stem through early infusion after influenza challenge	≤1:10	Participants who received placebo

Abbreviation: HA, hemagglutinin; HAI, hemagglutination inhibition; TCID$_{50}$, median tissue culture infectious dose.

1). Of note, 2 of the studies only included participants with HAI titers ≤1:40 [23, 24], 1 additional study only included participants with HAI titers ≤1:10 [25], and the fourth study included participants with both low and high HAI titers [19]. Participants who did not undergo influenza challenge, including those who were found to be infected with other respiratory viruses, were not included in analysis. An aggregate of 322 participants from the aforementioned studies were screened and after application of selection criteria, 164 participants were included in the analysis (Figure 1).

Ethical Considerations

The study was conducted in accordance with the provisions of the Declaration of Helsinki. Approval was obtained from the National Institute of Allergy and Infectious Diseases institutional review board and written consent was obtained from all participants.

Hormone Assays

Testosterone was tested using an enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions (Immuno-Biological Laboratories, Minneapolis, Minnesota). Estradiol was tested using an ELISA per the manufacturer's instructions (Calbiotech, El Cajon, California).

Immunologic and Virologic Assays

Assays were performed as previously described [19, 23]. HAI titers were measured against genetically identical virus to the challenge virus whereas NAI titers were measured using an enzyme-linked lectin assay using reassortant virus with a genetically identical NA to the challenge virus but a distinct HA subtype (H6), using previously reported standard methods [26, 27]. In brief, reassortant H6N1 and H6N2 viruses were mixed with serial dilutions of heat-inactivated participant sera and incubated overnight in 96-well plates coated with fetuin. Plates were washed and then peanut agglutinin conjugated to horseradish peroxidase was added. After a 2-hour incubation in the dark, plates were washed and o-phenylenediamine dihydrochloride was added. After 10 minutes in the dark, the reaction was quenched with sulfuric acid and the plates were read at 490 nm. Titers were assessed from a minimum dilution of 10 to a maximum of 640 for the FLU-V and CR6261 studies and 2560 for H1N1 pdMIST and HAI pdMIST. Titers below the minimum were coded as 1. All measurements were made in triplicate. Nasal washes were analyzed for viral shedding using 1-step real-time quantitative reverse-transcription polymerase chain reaction for the influenza A virus matrix 1 gene [28]. A standard curve with an external standard was used to calculate copy number.

Outcome Measures

Ages were presented as means. HAI and NAI titer raw data were available as titers and transformed ($\log_2$). Data were available at week 4 and week 8 postchallenge for H1N1 pdMIST and HAI pdMIST. Data were available for FLU-V at baseline, day 35 (approximated as week 4), and day 63 postchallenge (approximated as week 8). Data were available for CR6261 at baseline, day 29 (approximated as week 4), and day 66 (approximated as week 8). Presence of symptoms included proportions of participants who had any influenza-related symptoms at any time point. Presence of shedding included proportions of participants who had shedding of influenza at any time point. Mild to moderate influenza disease, defined as presence of shedding and symptoms, included proportions of participants who had both presence of symptoms and presence of shedding at any time point. Days of symptoms and days of shedding were presented as medians. Number of symptoms includes the number of different symptoms each participant had throughout the study period and was presented as a median.

Statistical Analysis

Data was collected in Excel and processed using RStudio version 1.1.463. Comparisons between sexes were performed using t tests for normally distributed variables (age, testosterone, prechallenge NAI titers, week 4 NAI titers, week 8 NAI titers), using Wilcoxon rank-sum tests for nonnormally distributed variables (estradiol, prechallenge HAI titers, week 4 HAI titers, week 8 HAI titers, days of shedding, days of symptoms, number of symptoms), and using tests of proportions or Fisher exact test for proportions. The analysis was repeated for the subgroup of participants with documented viral shedding. Differences and


Figure 1. Flow diagram of number of subjects from each dataset included for analysis after application of selection criteria, with breakdown by sex. Abbreviations: F, female; HAI, hemagglutination inhibition; M, male.

95% confidence intervals were provided for *t* tests. Interquartile ranges were provided for non–normally distributed variables. *P* values < .05 were considered statistically significant. No adjustment for multiple analyses was performed. Linear regression models were performed to examine outcomes (days of shedding, days of symptoms, number of symptoms) with age, sex, prechallenge estrogen level, prechallenge testosterone level, prechallenge HAI titer, and prechallenge NAI titer as predictor variables. Logistic regression models were performed to analyze outcomes (presence of shedding, presence of symptoms, mild to moderate influenza disease) with age, sex, prechallenge estrogen level, prechallenge testosterone level, prechallenge HAI titer, and prechallenge NAI titer as predictor variables. There was a small amount of missing data, particularly in antibody assays at day 28 (10 participants, all male), due to participant nonadherence with appointments.

RESULTS

Baseline Characteristics
Of the 164 participants included in the analysis, 91 were male and 73 were female. Age was similar between the sexes (Table 2). At baseline, testosterone levels were higher in males than females and estradiol levels were lower in males than females. Prechallenge geometric mean HAI titers were similar between males and females. Similarly, prechallenge geometric mean NAI titers were not significantly different between males and females.

Postchallenge Antibody Titers and Outcomes
Postchallenge geometric mean HAI titers rose at week 4 and 8 but were similar between males and females (Table 3, Supplementary Figure 1). The geometric mean NAI titers, however, were significantly greater in males compared to females at weeks 4 and 8 (Table 3, Supplementary Figure 2). Males were 16% less likely to have symptoms of influenza than females, though the likelihood of viral shedding was similar. Males had a median 4 days of symptoms, whereas females had a median 5 days of symptoms, though this did not reach statistical significance. Males had a significantly fewer median number of symptoms than females. Days of shedding did not significantly differ between males and females. Similar differences between sexes

were observed in a subgroup analysis of participants with viral shedding (Table 4), though the only outcome to retain statistical significance was the number of symptoms.

Predictive Modeling
Linear and logistic models (Table 5, Supplementary Tables 1–6) demonstrated that prechallenge NAI titers significantly predicted all outcomes (Supplementary Figures 3–8), which were presence of symptoms (*P* = .042), presence of shedding (*P* < .001), days of symptoms (*P* = .001), days of shedding (*P* < .001), number of symptoms (*P* < .001), and mild to moderate influenza disease (*P* < .001). Age, sex, baseline testosterone level, baseline estradiol level, and prechallenge HAI titers were not statistically significant predictors of outcomes. Tests of interactions between sex and all other covariates were not significant, with exception of an interaction between sex and prechallenge HAI titer for presence of shedding as outcome.

DISCUSSION

These findings add to a growing body of literature exploring sex differences in disease from influenza. Through analysis of data from healthy volunteer influenza challenge studies, we were able to overcome many of the limitations and confounding factors found in prior studies that have demonstrated sex differences with respect to clinical outcomes and antibody responses. We have demonstrated that clinical influenza disease experienced by females in our cohorts was worse compared to males. Specifically, a higher proportion of women experienced symptoms after challenge and women had more symptoms during their illness than men. Even among a subgroup of participants with evident infection demonstrated by active viral shedding, females had a higher number of symptoms. The rest of the observations lost their statistical significance, likely due to low sample size, though the trends of higher NAI titers in males and more severe symptoms in females persisted. These findings are in agreement with observations from retrospective studies showing that women have worse outcomes with influenza, even when accounting for comorbidities and exposure risk [10, 11].

Prior work has hypothesized that hormonal differences leading to transcriptional changes in immune cells may account for some of the variation in responses between sexes to influenza [5, 16, 29, 30]. The linear and logistic regression models

Table 2. Comparison of Baseline Characteristics Between Sexes Among Influenza Challenge Participants (n = 164)

Characteristic	Male (n = 91)	Female (n = 73)	Difference (95% CI)	*P* Value
Age, y, mean	29.3	29.8	−0.47 (−2.59 to 1.65)	.664
Testosterone, ng/mL, mean	5.84	0.93	4.91 (4.48–5.33)	<.001
Estradiol, pg/mL, median (IQR)	16.22 (12.55–24.21)	31.58 (17.38–64.8)	…	<.001
Prechallenge log$_2$ HAI titer, median (IQR)	0 (0–3.82)	0 (0–4.32)	…	.862
Prechallenge log$_2$ NAI titer, mean	6.55	5.94	0.60 (−.21 to 1.42)	.147

Means were compared by *t* test and medians by Wilcoxon-rank sum test.

Abbreviations: CI, confidence interval; HAI, hemagglutination inhibition; IQR, interquartile range; NAI, neuraminidase inhibition.

Table 3. Comparison of Postchallenge Outcomes Between Sexes Among Influenza Challenge Participants (n = 164)

Outcome	Male (n = 91)	Female (n = 73)	Difference (95% CI)	P Value
Week 4 log$_2$ HAI titer, median (IQR)	5.32 (3.32–6.32)	4.82 (2.49–6.32)	…	.784
Week 8 log$_2$ HAI titer, median (IQR)	4.32 (0–6.32)	5.32 (0–6.32)	…	.733
Week 4 log$_2$ NAI titer, mean	7.95	7.33	0.62 (.01–1.23)	.046
Week 8 log$_2$ NAI titer, mean	8.03	7.39	0.64 (.03–1.25)	.039
Presence of symptoms	0.80	0.96	−0.16 (.06–.25)	.003
Presence of shedding	0.62	0.60	−0.01 (−.16 to .14)	.869
Mild to moderate influenza disease	0.56	0.59	−0.03 (−.12 to .18)	.7129
Days of symptoms, median (IQR)	4 (1–7)	5 (3–7)	…	.064
No. of symptoms, median (IQR)	3 (1–5)	4 (2–7)	…	.011
Days of shedding, median (IQR)	1 (0–4.5)	2 (0–6)	…	.486

Medians were compared by Wilcoxon-rank sum test, means by *t* test, and proportions using test of proportions.

Abbreviations: CI, confidence interval; HAI, hemagglutination inhibition; IQR, interquartile range; NAI, neuraminidase inhibition.

constructed in this study did not find that baseline testosterone or estradiol levels were predictive of outcomes. Despite prior studies showing that postvaccination HAI titers were higher in women than men [17, 18], this study found no differences at 4 or 8 weeks after inoculation with a live wild-type challenge virus. However, 3 of 4 data sets in this study restricted participation to participants with lower HAI titers, which potentially selected for participants with poor immunologic responses to HA compared to the general population, potentially obscuring differences between the sexes. Serum NAI titers were higher in males than females after challenge, reaching statistical significance at 4 weeks and 8 weeks postchallenge but not at the prechallenge timepoint. Interestingly, all models identified prechallenge NAI titers as the highly significant variable predictive of all disease outcomes of interest. Sex itself was not a significant predictor variable, suggesting that differences in prechallenge NAI titers, once adjusted for other variables, underlie some of differences in outcomes observed between males and females. This finding is consistent with previous work demonstrating that anti-NA antibodies are pivotal in decreasing symptoms and attenuating disease severity [19, 20, 31, 32]. Two of the challenge studies [19, 25] used for this analysis already determined the importance of anti-NA antibodies in protection against influenza challenge, but importantly, the addition of 2 additional datasets

only reinforced this finding. This further supports recent efforts drawing attention to the importance of immunity against NA to develop novel therapeutics and vaccines with improved efficacy and breadth of protection [21, 33, 34]. The protection afforded by anti-NA antibodies is generally considered infection permissive and is consistent with the similar rates of infection in the male and female subgroups despite differences in NAI titers [35]. However, it is important to note that it is unknown whether the artificial manner of inoculation with a single spray of a large inoculum of virus manifests any clinical differences from natural infection, which typically arises from longer exposure times.

The overall higher NAI titers seen in male participants provide a potential mechanism to explain some of the differences in symptom-related outcomes between sexes observed in this study, while acknowledging that the difference in NAI titers between sexes did not quite reach statistical significance at baseline. However, the difference became significant at both postchallenge timepoints, suggesting the possibility that males have a better NAI memory response during the early days of the infection, from which we do not have data. Additional features of anti-influenza immunity that were not measured could also potentially play important roles in sex-based differences in the pathogenesis of influenza. Cell-mediated immunity was not

Table 4. Comparison of Postchallenge Outcomes Between Sexes Among Participants With Influenza Viral Shedding (n = 100)

Outcome	Male (n = 56)	Female (n = 44)	Difference (95% CI)	P Value
Week 4 log$_2$ HAI titer, median (IQR)	4.82 (3.32–6.07)	4.32 (0–6.32)	…	.839
Week 8 log$_2$ HAI titer, median (IQR)	4.32 (0–5.32)	4.32 (0–6.32)	…	.797
Week 4 log$_2$ NAI titer, mean	7.58	7.17	0.41 (−.41 to 1.23)	.328
Week 8 log$_2$ NAI titer, mean	7.87	7.22	0.65 (−.15 to 1.45)	.112
Presence of symptoms	0.91	0.98	…	.225
Days of symptoms, median (IQR)	6 (3–8)	6 (4–9)	…	.368
No. of symptoms, median (IQR)	3.5 (2–6)	5 (2–10)	…	.047
Days of shedding, median (IQR)	4 (1–6)	5 (2–6)	…	.084

Data are presented as medians, means, or proportions. Medians were compared by Wilcoxon-rank sum test, means by *t* test, and proportions using test of proportions or Fisher exact test.

Abbreviations: CI, confidence interval; HAI, hemagglutination inhibition; IQR, interquartile range; NAI, neuraminidase inhibition.

Table 5. Outcomes of Interest and Significant Predictor Variables Obtained Using Linear and Logistic Regression Models

Outcome of Interest	Predictor Variables	P Value
Presence of symptoms	Sex	.089
	Age	.658
	Estrogen	.535
	Testosterone	.729
	Prechallenge $\log_2$ HAI titer	.842
	Prechallenge $\log_2$ NAI titer	.042
Presence of shedding	Sex	.418
	Age	.107
	Estrogen	.675
	Testosterone	.840
	Prechallenge $\log_2$ HAI titer	.451
	Prechallenge $\log_2$ NAI titer	<.001
	Sex × prechallenge $\log_2$ HAI titer	.046
Days of symptoms	Sex	.442
	Age	.799
	Estrogen	.959
	Testosterone	.663
	Prechallenge $\log_2$ HAI titer	1.000
	Prechallenge $\log_2$ NAI titer	.001
Days of shedding	Sex	.400
	Age	.337
	Estrogen	.608
	Testosterone	.508
	Prechallenge $\log_2$ HAI titer	.096
	Prechallenge $\log_2$ NAI titer	<.001
No. of symptoms	Sex	.131
	Age	.618
	Estrogen	.554
	Testosterone	.576
	Prechallenge $\log_2$ HAI titer	.605
	Prechallenge $\log_2$ NAI titer	<.001
Mild to moderate influenza disease	Sex	.262
	Age	.270
	Estrogen	.524
	Testosterone	.250
	Prechallenge $\log_2$ HAI titer	.207
	Prechallenge $\log_2$ NAI titer	.001

Abbreviations: HAI, hemagglutination inhibition; NAI, neuraminidase inhibition.

measured in this study but is known to be a significant factor in cross-protective immunity against influenza [36]. Furthermore, mucosal immunity is likely to play an underappreciated role in protection, especially against mild infections of the upper respiratory tract [37, 38]. Future models integrating these measures, including mucosal levels of anti-NA antibodies, may be better equipped to explain the relationships between sex and outcomes with influenza.

Despite the aforementioned benefits of influenza challenge studies, there are some limitations inherent to challenge studies in general, and to the specific characteristics of the cohorts used in this study. Volunteers with baseline HAI titers <1:40 were selected to participate in 2 of the 4 studies (and HAI titers <1:10 in a third study), leading to a specially curated population with decreased external validity.

Confounding may also have been introduced by differences in inclusion/exclusion criteria between studies and unequal proportions of male and female participants in each cohort. Unlike antibody levels, hormone levels are known to oscillate over short periods of time and our single measurement may be insufficient to completely rule out a relationship to clinical outcomes. Furthermore, even though data collection of symptoms was standardized, there may still be differences in reporting among sexes. Use of more objective outcome measures, such as markers of inflammation, may be helpful in supporting the conclusions of this study. Finally, the analysis between sexes and the regression models was not adjusted for multiple comparisons, which may weaken the meaningfulness of some observations but would be unlikely to impact the highly statistically significant predictive capacity of NAI titers in the regression models.

These data agree with published observations that females of reproductive age have worse outcomes during influenza infection. In this study, NAI titers were a predictor of clinical outcomes after influenza challenge, suggesting the possibility that anti-NA antibodies may underlie differences between sexes. The majority of participants in these studies, however, were specifically selected to have low HAI titers. Future studies in more general populations, ideally including additional variables like cell-mediated and mucosal immunity, are needed to confirm the differences in NAI titers between sexes observed here and to validate and refine the predictive models.

Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

References

1. vom Steeg LG, Klein SL. SeXX matters in infectious disease pathogenesis. PLoS Pathog **2016**; 12:e1005374.
2. Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity **2020**; 53:487–95.

3. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol **2016**; 16:626–38.

4. Morgan R, Klein SL. The intersection of sex and gender in the treatment of influenza. Curr Opin Virol **2019**; 35:35–41.

5. Robinson DP, Lorenzo ME, Jian W, Klein SL. Elevated 17β-estradiol protects females from influenza A virus pathogenesis by suppressing inflammatory responses. PLoS Pathog **2011**; 7:e1002149.

6. Lorenzo ME, Hodgson A, Robinson DP, Kaplan JB, Pekosz A, Klein SL. Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice. Vaccine **2011**; 29:9246–55.

7. Vermillion MS, Ursin RL, Kuok DIT, et al. Production of amphiregulin and recovery from influenza is greater in males than females. Biol Sex Differ **2018**; 9:24.

8. Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci U S A **2018**; 115:12477–82.

9. Vom Steeg LG, Dhakal S, Woldetsadik YA, et al. Androgen receptor signaling in the lungs mitigates inflammation and improves the outcome of influenza in mice. PLoS Pathog **2020**; 16:e1008506.

10. Eshima N, Tokumaru O, Hara S, et al. Sex- and age-related differences in morbidity rates of 2009 pandemic influenza A H1N1 virus of swine origin in Japan. PLoS One **2011**; 6:e19409.

11. Kumar A, Zarychanski R, Pinto R, et al; Canadian Critical Care Trials Group H1N1 Collaborative. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA **2009**; 302:1872–9.

12. Wong KC, Luscombe GM, Hawke C. Influenza infections in Australia 2009-2015: is there a combined effect of age and sex on susceptibility to virus subtypes?. BMC Infect Dis **2019**; 19:42.

13. Mertz D, Lo CK, Lytvyn L, Ortiz JR, Loeb M; FLURISK-Investigators. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis. BMC Infect Dis **2019**; 19:683.

14. World Health Organization. Sex, gender and influenza. Geneva, Switzerland: WHO, **2010**.

15. Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol **2017**; 33:577–99.

16. Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A **2014**; 111:869–74.

17. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med **2006**; 166:1121–7.

18. Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med **2008**; 168:2405–14.

19. Memoli MJ, Shaw PA, Han A, et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. mBio **2016**; 7:200417–16.

20. Maier HE, Nachbagauer R, Kuan G, et al. Pre-existing antineuraminidase antibodies are associated with shortened duration of influenza A(H1N1)pdm virus shedding and illness in naturally infected adults. Clin Infect Dis **2020**; 70:2290–7.

21. Giurgea LT, Morens DM, Taubenberger JK, Memoli MJ. Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine. Vaccines (Basel) **2020**; 8:409.

22. Anker M. Addressing sex and gender in epidemic-prone infectious diseases. Geneva, Switzerland: World Health Organization, **2007**.

23. Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis **2015**; 60:693–702.

24. Pleguezuelos O, James E, Fernandez A, et al. Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study. NPJ Vaccines **2020**; 5:22.

25. Han A, Czajkowski L, Rosas LA, et al. Safety and efficacy of CR6261 in an influenza A H1N1 healthy human challenge model [manuscript published online ahead of print 19 November 2020]. Clin Infect Dis **2020**. doi:10.1093/cid/ciaa1725.

26. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull **1979**; 35:69–75.

27. Wan H, Gao J, Xu K, et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol **2013**; 87:9290–300.

28. Krafft AE, Russell KL, Hawksworth AW, et al. Evaluation of PCR testing of ethanol-fixed nasal swab specimens as an augmented surveillance strategy for influenza virus and adenovirus identification. J Clin Microbiol **2005**; 43:1768–75.

29. Piasecka B, Duffy D, Urrutia A, et al; Milieu Intérieur Consortium. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. Proc Natl Acad Sci U S A **2018**; 115:E488–97.

30. Bongen E, Lucian H, Khatri A, et al. Sex differences in the blood transcriptome identify robust changes in immune cell proportions with aging and influenza infection. Cell Rep **2019**; 29:1961–73.e4.

31. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. Lancet **1973**; 1:623–5.

32. Monto AS, Petrie JG, Cross RT, et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis **2015**; 212:1191–9.

33. Eichelberger MC, Monto AS. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J Infect Dis **2019**; 219:75–80.

34. Stadlbauer D, Zhu X, McMahon M, et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science **2019**; 366:499–504.

35. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine **1993**; 11:1037–9.

36. Jansen JM, Gerlach T, Elbahesh H, Rimmelzwaan GF, Saletti G. Influenza virus-specific CD4[+] and CD8[+] T cell-mediated immunity induced by infection and vaccination. J Clin Virol **2019**; 119:44–52.

37. McMahon M, Kirkpatrick E, Stadlbauer D, Strohmeier S, Bouvier NM, Krammer F. Mucosal immunity against neuraminidase prevents influenza B virus transmission in guinea pigs. MBio **2019**; 10: e00560-19.

38. Chen K, Magri G, Grasset EK, Cerutti A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat Rev Immunol **2020**; 20:427–41.